A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113

Diseases and Conditions Researched

Advanced Malignancies; Anaplastic Large Cell Lymphoma; Carcinoma, Non-Small-Cell Lung; Diffuse Large Cell Lymphoma; Inflammatory Myofibroblastic Tumors

Participation Guidelines

Age: 18 Years and older
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Ariad Pharmaceuticals
Dates: September 30, 2011
Last Updated: July 12, 2013
Clinicaltrials.gov ID: NCT01449461